布比卡因脂质体和盐酸布比卡因在儿童腔镜疝修补术中行腹横肌平面神经阻滞对术后疼痛的影响:一项随机、开放标签、平行对照设计临床研究

注册号:

Registration number:

ChiCTR2500115858 

最近更新日期:

Date of Last Refreshed on:

2025-12-31 17:14:03 

注册时间:

Date of Registration:

2025-12-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

布比卡因脂质体和盐酸布比卡因在儿童腔镜疝修补术中行腹横肌平面神经阻滞对术后疼痛的影响:一项随机、开放标签、平行对照设计临床研究

Public title:

The effect of liposomal bupivacaine and bupivacaine hydrochloride on postoperative pain during laparoscopic repair of inguinal hernia in children with transverse abdominis muscle plane nerve block: a randomized, Open-label, parallel controlled clinical study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

布比卡因脂质体和盐酸布比卡因在儿童腔镜疝修补术中行腹横肌平面神经阻滞对术后疼痛的影响:一项随机、开放标签、平行对照设计临床研究

Scientific title:

The effect of liposomal bupivacaine and bupivacaine hydrochloride on postoperative pain during laparoscopic repair of inguinal hernia in children with transverse abdominis muscle plane nerve block: a randomized, Open-label, parallel controlled clinical study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

欧阳云鹏 

研究负责人:

欧阳云鹏 

Applicant:

Yunpeng Ouyang 

Study leader:

Yunpeng Ouyang 

申请注册联系人电话:

Applicant telephone:

+86 175 2133 5430

研究负责人电话:

Study leader's
telephone:

+86 175 2133 5430

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ouyang19971118@163.com

研究负责人电子邮件:

Study leader's E-mail:

ouyang19971118@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区东方路1678号

研究负责人通讯地址:

上海市浦东新区东方路1678号

Applicant address:

1678 Dongfang Road, Pudong New Area, Shanghai

Study leader's address:

1678 Dongfang Road, Pudong New Area, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学医学院附属上海儿童医学中心

Applicant's institution:

Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine

研究负责人所在单位:

上海交通大学医学院附属上海儿童医学中心

Affiliation of the Leader:

Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SCMCIRB-K2025280-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海交通大学医学院·附属上海儿童医学中心伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-20 00:00:00

伦理委员会联系人:

任益炯

Contact Name of the ethic committee:

Ren Yijiong

伦理委员会联系地址:

上海市浦东新区东方路1678号

Contact Address of the ethic committee:

1678 Dongfang Road, Pudong New Area, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 3862 6161

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属上海儿童医学中心

Primary sponsor:

Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine

研究实施负责(组长)单位地址:

上海市浦东新区东方路1678号

Primary sponsor's address:

1678 Dongfang Road, Pudong New Area, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属上海儿童医学中心

具体地址:

上海市浦东新区东方路1678号

Institution
hospital:

Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine

Address:

1678 Dongfang Road, Pudong New Area, Shanghai

经费或物资来源:

自筹

Source(s) of funding:

self-raised

研究疾病:

疝气  

Target disease:

hernia

研究疾病代码:

SB07

Target disease code:

SB07

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

与盐酸布比卡因比较,评估使用布比卡因脂质体行腹横肌平面神经阻滞对儿童腔镜疝修补术术后疼痛的影响。  

Objectives of Study:

Compared with bupivacaine hydrochloride, evaluate the effect of using bupivacaine liposomes for transversus abdominis plane nerve block on postoperative pain in children undergoing laparoscopic hernia repair.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.智力发育迟缓,不能理解语言的患儿; 2.近期接受过其他手术的患儿; 3.存在腹部神经阻滞禁忌症; 4.肝肾功能不全者; 5.正在参加其他临床试验者; 6.拒绝签署知情同意书或术后补救镇痛的病人。

Exclusion criteria:

1. Children with delayed intellectual development and inability to understand language; 2. Children who have recently undergone other surgeries; 3. There are contraindications for abdominal nerve block; 4. Patients with liver and kidney dysfunction; 5. Participants in other clinical trials; 6. Patients who refuse to sign informed consent forms or undergo postoperative pain relief.

研究实施时间:

Study execute time:

From 2025-12-01 00:00:00 To 2026-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-01 00:00:00 To 2026-12-01 00:00:00

干预措施:

Interventions:

组别:

试验组(BL 组)

样本量:

100

Group:

Experimental group (BL group)

Sample size:

干预措施:

使用布比卡因脂质体注射液行 TAP 神经阻滞。

干预措施代码:

Intervention:

Use bupivacaine liposome injection for TAP nerve block.

Intervention code:

组别:

对照组(BH 组)

样本量:

100

Group:

Control group (BH group)

Sample size:

干预措施:

使用布比卡因注射液行 TAP 神经阻滞。

干预措施代码:

Intervention:

Use bupivacaine injection for TAP nerve block.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属上海儿童医学中心 

单位级别:

三甲 

Institution
hospital:

Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛数字评分量表评分

指标类型:

主要指标

Outcome:

Numerical Rating Scale of pain

Type:

Primary indicator

测量时间点:

术后 1h(±10min)(出 PACU 时)、6h(±2h)、12h(±2h)、24h(±2h)、 36h(±2h),48h(±2h)、60h(±2h)、72h(±2h)

测量方法:

Measure time point of outcome:

Postoperative 1 hour (+/- 10 minutes) (at the time of PACU release), 6 hours (+/- 2 hours), 12 hours (+/- 2 hours), 24 hours (+/- 2 hours), 36 hours (+/- 2 hours), 48 hours (+/- 2 hours), 60 hours (+/- 2 hours), 72 hours (+/- 2 hours)

Measure method:

指标中文名:

首次接受补救镇痛的时间

指标类型:

次要指标

Outcome:

The time of first receipt of remedial analgesia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者住院期间的补救镇痛次数

指标类型:

主要指标

Outcome:

The frequency of remedial analgesia during the patient's hospitalization

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

年龄

指标类型:

附加指标

Outcome:

age

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

性别

指标类型:

附加指标

Outcome:

gender

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身高

指标类型:

附加指标

Outcome:

height

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

附加指标

Outcome:

weight

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 6 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用随机区组设计。由与本研究数据收集和管理分析无关的统计专家,使用 SAS 统计软件包,按照试验组和对照组 1:1 的比例产生随机数字。

Randomization Procedure (please state who generates the random number sequence and by what method):

Adopting a randomized block design, by statistical experts unrelated to the data collection and management analysis of this study.Use SAS statistical software package to generate random numbers in a 1:1 ratio between the experimental group and the control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

None

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-12-31 17:13:42